<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39456150</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2218-273X</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>26</Day></PubDate></JournalIssue><Title>Biomolecules</Title><ISOAbbreviation>Biomolecules</ISOAbbreviation></Journal><ArticleTitle>T Cell Peptide Prediction, Immune Response, and Host-Pathogen Relationship in Vaccinated and Recovered from Mild COVID-19 Subjects.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1217</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biom14101217</ELocationID><Abstract><AbstractText>COVID-19 remains a significant threat, particularly to vulnerable populations. The emergence of new variants necessitates the development of treatments and vaccines that induce both humoral and cellular immunity. This study aimed to identify potentially immunogenic SARS-CoV-2 peptides and to explore the intricate host-pathogen interactions involving peripheral immune responses, memory profiles, and various demographic, clinical, and lifestyle factors. Using in silico and experimental methods, we identified several CD8-restricted SARS-CoV-2 peptides that are either poorly studied or have previously unreported immunogenicity: fifteen from the Spike and three each from non-structural proteins Nsp1-2-3-16. A Spike peptide, LA-9, demonstrated a 57% response rate in ELISpot assays using PBMCs from 14 HLA-A*02:01 positive, vaccinated, and mild-COVID-19 recovered subjects, indicating its potential for diagnostics, research, and multi-epitope vaccine platforms. We also found that younger individuals, with fewer vaccine doses and longer intervals since infection, showed lower anti-Spike (ELISA) and anti-Wuhan neutralizing antibodies (pseudovirus assay), higher naïve T cells, and lower central memory, effector memory, and CD4hiCD8low T cells (flow cytometry) compared to older subjects. In our cohort, a higher prevalence of Vδ2-γδ and DN T cells, and fewer naïve CD8 T cells, seemed to correlate with strong cellular and lower anti-NP antibody responses and to associate with Omicron infection, absence of confusional state, and habitual sporting activity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Macchia</LastName><ForeName>Iole</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-3870-8202</Identifier><AffiliationInfo><Affiliation>Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>La Sorsa</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Research Promotion and Coordination Service, Istituto Superiore di Sanità, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciervo</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0664-9375</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruspantini</LastName><ForeName>Irene</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Core Facilities, Istituto Superiore di Sanità, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Negri</LastName><ForeName>Donatella</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-3437-9288</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borghi</LastName><ForeName>Martina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Angelis</LastName><ForeName>Maria Laura</ForeName><Initials>ML</Initials><Identifier Source="ORCID">0000-0003-4220-8822</Identifier><AffiliationInfo><Affiliation>Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luciani</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-1362-2808</Identifier><AffiliationInfo><Affiliation>National Center for the Control and Evaluation of Medicines, Istituto Superiore di Sanità, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martina</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>National Center for the Control and Evaluation of Medicines, Istituto Superiore di Sanità, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taglieri</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><Identifier Source="ORCID">0009-0008-1939-4982</Identifier><AffiliationInfo><Affiliation>Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Durastanti</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Neurology Unit, San Filippo Neri Hospital, ASL RM1, 00135 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Altavista</LastName><ForeName>Maria Concetta</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Neurology Unit, San Filippo Neri Hospital, ASL RM1, 00135 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Urbani</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-5522-2706</Identifier><AffiliationInfo><Affiliation>Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mancini</LastName><ForeName>Fabiola</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ISS/DON12/2021</GrantID><Agency>Istituto Superiore di Sanità</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomolecules</MedlineTA><NlmUniqueID>101596414</NlmUniqueID><ISSNLinking>2218-273X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018984">Epitopes, T-Lymphocyte</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054884" MajorTopicYN="Y">Host-Pathogen Interactions</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018984" MajorTopicYN="N">Epitopes, T-Lymphocyte</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">ELISpot</Keyword><Keyword MajorTopicYN="N">T cell epitopes</Keyword><Keyword MajorTopicYN="N">T peptide</Keyword><Keyword MajorTopicYN="N">bioinformatics</Keyword><Keyword MajorTopicYN="N">neutralizing antibodies</Keyword></KeywordList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39456150</ArticleId><ArticleId IdType="pmc">PMC11505848</ArticleId><ArticleId IdType="doi">10.3390/biom14101217</ArticleId><ArticleId IdType="pii">biom14101217</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Carabelli A.M., Peacock T.P., Thorne L.G., Harvey W.T., Hughes J., de Silva T.I., Peacock S.J., Barclay W.S., de Silva T.I., Towers G.J., et al. SARS-CoV-2 variant biology: Immune escape, transmission and fitness. Nat. Rev. Microbiol. 2023;21:162–177. doi: 10.1038/s41579-022-00841-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00841-7</ArticleId><ArticleId IdType="pmc">PMC9847462</ArticleId><ArticleId IdType="pubmed">36653446</ArticleId></ArticleIdList></Reference><Reference><Citation>Hachmann N.P., Miller J., Collier A.Y., Ventura J.D., Yu J., Rowe M., Bondzie E.A., Powers O., Surve N., Hall K., et al. Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5. N. Engl. J. Med. 2022;387:86–88. doi: 10.1056/NEJMc2206576.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2206576</ArticleId><ArticleId IdType="pmc">PMC9258748</ArticleId><ArticleId IdType="pubmed">35731894</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhlmann C., Mayer C.K., Claassen M., Maponga T., Burgers W.A., Keeton R., Riou C., Sutherland A.D., Suliman T., Shaw M.L., et al. Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose. Lancet. 2022;399:625–626. doi: 10.1016/S0140-6736(22)00090-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00090-3</ArticleId><ArticleId IdType="pmc">PMC8765759</ArticleId><ArticleId IdType="pubmed">35063123</ArticleId></ArticleIdList></Reference><Reference><Citation>Polatoğlu I. COVID-19 in early 2023: Structure, replication mechanism, variants of SARS-CoV-2, diagnostic tests, and vaccine &amp; drug development studies. MedComm. 2023;4:e228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10082934</ArticleId><ArticleId IdType="pubmed">37041762</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunagar R., Singh A., Kumar S. SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines. Vaccines. 2023;11:849. doi: 10.3390/vaccines11040849.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11040849</ArticleId><ArticleId IdType="pmc">PMC10143972</ArticleId><ArticleId IdType="pubmed">37112761</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen J., Fan J., Zhao Y., Jiang D., Niu Z., Zhang Z., Cao G. Innate and adaptive immunity to SARS-CoV-2 and predisposing factors. Front. Immunol. 2023;14:1159326. doi: 10.3389/fimmu.2023.1159326.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1159326</ArticleId><ArticleId IdType="pmc">PMC10203583</ArticleId><ArticleId IdType="pubmed">37228604</ArticleId></ArticleIdList></Reference><Reference><Citation>Moga E., Lynton-Pons E., Domingo P. The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection. Front. Immunol. 2022;13:904686. doi: 10.3389/fimmu.2022.904686.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.904686</ArticleId><ArticleId IdType="pmc">PMC9271749</ArticleId><ArticleId IdType="pubmed">35833134</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Li Q., Qiu Y.W., Lu H. COVID-19: Imbalanced cell-mediated immune response drives to immunopathology. Emerg. Microbes Infect. 2022;11:2393–2404. doi: 10.1080/22221751.2022.2122579.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2022.2122579</ArticleId><ArticleId IdType="pmc">PMC9553190</ArticleId><ArticleId IdType="pubmed">36069182</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamińska D., Dęborska-Materkowska D., Kościelska-Kasprzak K., Mazanowska O., Remiorz A., Poznański P., Durlik M., Krajewska M. Immunity after COVID-19 Recovery and Vaccination: Similarities and Differences. Vaccines. 2022;10:1068. doi: 10.3390/vaccines10071068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10071068</ArticleId><ArticleId IdType="pmc">PMC9322013</ArticleId><ArticleId IdType="pubmed">35891232</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah V.K., Firmal P., Alam A., Ganguly D., Chattopadhyay S. Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past. Front. Immunol. 2020;11:1949. doi: 10.3389/fimmu.2020.01949.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01949</ArticleId><ArticleId IdType="pmc">PMC7426442</ArticleId><ArticleId IdType="pubmed">32849654</ArticleId></ArticleIdList></Reference><Reference><Citation>Vabret N., Britton G.J., Gruber C., Hegde S., Kim J., Kuksin M., Levantovsky R., Malle L., Moreira A., Park M.D., et al. Immunology of COVID-19: Current State of the Science. Immunity. 2020;52:910–941. doi: 10.1016/j.immuni.2020.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.05.002</ArticleId><ArticleId IdType="pmc">PMC7200337</ArticleId><ArticleId IdType="pubmed">32505227</ArticleId></ArticleIdList></Reference><Reference><Citation>Menges D., Zens K.D., Ballouz T., Caduff N., Llanas-Cornejo D., Aschmann H.E., Domenghino A., Pellaton C., Perreau M., Fenwick C., et al. Heterogenous humoral and cellular immune responses with distinct trajectories post-SARS-CoV-2 infection in a population-based cohort. Nat. Commun. 2022;13:4855. doi: 10.1038/s41467-022-32573-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32573-w</ArticleId><ArticleId IdType="pmc">PMC9386650</ArticleId><ArticleId IdType="pubmed">35982045</ArticleId></ArticleIdList></Reference><Reference><Citation>Grifoni A., Weiskopf D., Ramirez S.I., Mateus J., Dan J.M., Moderbacher C.R., Rawlings S.A., Sutherland A., Premkumar L., Jadi R.S., et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020;181:1489–1501. doi: 10.1016/j.cell.2020.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.05.015</ArticleId><ArticleId IdType="pmc">PMC7237901</ArticleId><ArticleId IdType="pubmed">32473127</ArticleId></ArticleIdList></Reference><Reference><Citation>Juno J.A., Tan H.X., Lee W.S., Reynaldi A., Kelly H.G., Wragg K., Esterbauer R., Kent H.E., Batten C.J., Mordant F.L., et al. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat. Med. 2020;26:1428–1434. doi: 10.1038/s41591-020-0995-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0995-0</ArticleId><ArticleId IdType="pubmed">32661393</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng K., Faulkner N., Cornish G., Rosa A., Earl C., Wrobel A., Benton D., Roustan C., Bolland W., Thompson R., et al. Pre-existing and de novo humoral immunity to SARS-CoV-2 in humans. Science. 2020;370:1343–1399. doi: 10.1126/science.abe1107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abe1107</ArticleId><ArticleId IdType="pmc">PMC7857411</ArticleId><ArticleId IdType="pubmed">33159009</ArticleId></ArticleIdList></Reference><Reference><Citation>Phua J., Weng L., Ling L., Egi M., Lim C.M., Divatia J.V., Shrestha B.R., Arabi Y.M., Ng J., Gomersall C.D., et al. Intensive care management of coronavirus disease 2019 (COVID-19): Challenges and recommendations. Lancet Respir. Med. 2020;8:506–517. doi: 10.1016/S2213-2600(20)30161-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30161-2</ArticleId><ArticleId IdType="pmc">PMC7198848</ArticleId><ArticleId IdType="pubmed">32272080</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldblatt D., Alter G., Crotty S., Plotkin S.A. Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. Immunol. Rev. 2022;310:6–26. doi: 10.1111/imr.13091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.13091</ArticleId><ArticleId IdType="pmc">PMC9348242</ArticleId><ArticleId IdType="pubmed">35661178</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi H., Liu B., Wang X., Zhang L. The humoral response and antibodies against SARS-CoV-2 infection. Nat. Immunol. 2022;23:1008–1020. doi: 10.1038/s41590-022-01248-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-022-01248-5</ArticleId><ArticleId IdType="pubmed">35761083</ArticleId></ArticleIdList></Reference><Reference><Citation>Moss P. Nature Immunology. Volume 23. Springer; New York, NY, USA: 2022. The T cell immune response against SARS-CoV-2; pp. 186–193.</Citation><ArticleIdList><ArticleId IdType="pubmed">35105982</ArticleId></ArticleIdList></Reference><Reference><Citation>Tada T., Peng J.Y., Dcosta B.M., Landau N.R. Single-epitope T cell-based vaccine protects against SARS-CoV-2 infection in a preclinical animal model. JCI Insight. 2023;8:e167306. doi: 10.1172/jci.insight.167306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.167306</ArticleId><ArticleId IdType="pmc">PMC10132166</ArticleId><ArticleId IdType="pubmed">37036004</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf D., Schmitz K.S., Raadsen M.P., Grifoni A., Okba N.M.A., Endeman H., van den Akker J.P.C., Molenkamp R., Koopmans M.P.G., van Gorp E.C.M., et al. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. Sci. Immunol. 2020;5:eabd2071. doi: 10.1126/sciimmunol.abd2071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abd2071</ArticleId><ArticleId IdType="pmc">PMC7319493</ArticleId><ArticleId IdType="pubmed">32591408</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilich T., Nelde A., Heitmann J.S., Maringer Y., Roerden M., Bauer J., Rieth J., Wacker M., Peter A., Horber S., et al. T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-Term immune responses in COVID-19 convalescent individuals. Sci. Transl. Med. 2021;13:17–20. doi: 10.1126/scitranslmed.abf7517.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abf7517</ArticleId><ArticleId IdType="pmc">PMC8128286</ArticleId><ArticleId IdType="pubmed">33723016</ArticleId></ArticleIdList></Reference><Reference><Citation>Sette A., Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184:861–880. doi: 10.1016/j.cell.2021.01.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.01.007</ArticleId><ArticleId IdType="pmc">PMC7803150</ArticleId><ArticleId IdType="pubmed">33497610</ArticleId></ArticleIdList></Reference><Reference><Citation>Malonis R.J., Lai J.R., Vergnolle O. Peptide-Based Vaccines: Current Progress and Future Challenges. Chem. Rev. 2020;120:3210–3229. doi: 10.1021/acs.chemrev.9b00472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.chemrev.9b00472</ArticleId><ArticleId IdType="pmc">PMC7094793</ArticleId><ArticleId IdType="pubmed">31804810</ArticleId></ArticleIdList></Reference><Reference><Citation>Feikin D.R., Higdon M.M., Abu-Raddad L.J., Andrews N., Araos R., Goldberg Y., Groome M.J., Huppert A., O’Brien K.L., Smith P.G., et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: Results of a systematic review and meta-regression. Lancet. 2022;399:924–944. doi: 10.1016/S0140-6736(22)00152-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00152-0</ArticleId><ArticleId IdType="pmc">PMC8863502</ArticleId><ArticleId IdType="pubmed">35202601</ArticleId></ArticleIdList></Reference><Reference><Citation>Kedzierska K., Thomas P.G. Count on us: T cells in SARS-CoV-2 infection and vaccination. Cell Reports Med. 2022;3:100562. doi: 10.1016/j.xcrm.2022.100562.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100562</ArticleId><ArticleId IdType="pmc">PMC8872824</ArticleId><ArticleId IdType="pubmed">35474748</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Z., Ruan P., Wang L., Nie X., Ma X., Tan Y. T and B cell Epitope analysis of SARS-CoV-2 S protein based on immunoinformatics and experimental research. J. Cell. Mol. Med. 2021;25:1274–1289. doi: 10.1111/jcmm.16200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.16200</ArticleId><ArticleId IdType="pmc">PMC7812294</ArticleId><ArticleId IdType="pubmed">33325143</ArticleId></ArticleIdList></Reference><Reference><Citation>Heitmann J.S., Tandler C., Marconato M., Nelde A., Habibzada T., Rittig S.M., Tegeler C.M., Maringer Y., Jaeger S.U., Denk M., et al. Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency. Nat. Commun. 2023;14:5032. doi: 10.1038/s41467-023-40758-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-40758-0</ArticleId><ArticleId IdType="pmc">PMC10439231</ArticleId><ArticleId IdType="pubmed">37596280</ArticleId></ArticleIdList></Reference><Reference><Citation>Paramithiotis E., Sugden S., Papp E., Bonhomme M., Chermak T., Crawford S.Y., Demetriades S.Z., Galdos G., Lambert B.L., Mattison J., et al. Cellular Immunity Is Critical for Assessing COVID-19 Vaccine Effectiveness in Immunocompromised Individuals. Front. Immunol. 2022;13:880784. doi: 10.3389/fimmu.2022.880784.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.880784</ArticleId><ArticleId IdType="pmc">PMC9179228</ArticleId><ArticleId IdType="pubmed">35693815</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis M.J. Recent Advances in Vaccine Technologies. Vet. Clin. North Am. Small Anim. Pract. 2018;48:231–241. doi: 10.1016/j.cvsm.2017.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cvsm.2017.10.002</ArticleId><ArticleId IdType="pmc">PMC7132473</ArticleId><ArticleId IdType="pubmed">29217317</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim H.X., Lim J., Jazayeri S.D., Poppema S., Poh C.L. Development of multi-epitope peptide-based vaccines against SARS-CoV-2. Biomed. J. 2020;44:18–30. doi: 10.1016/j.bj.2020.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bj.2020.09.005</ArticleId><ArticleId IdType="pmc">PMC7527307</ArticleId><ArticleId IdType="pubmed">33727051</ArticleId></ArticleIdList></Reference><Reference><Citation>Moroy G., Tuffery P. Peptide-Based Strategies Against SARS-CoV-2 Attack: An Updated In Silico Perspective. Front. Drug Discov. 2022;2:899477. doi: 10.3389/fddsv.2022.899477.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fddsv.2022.899477</ArticleId></ArticleIdList></Reference><Reference><Citation>Saldanha L., Langel Ü., Vale N. In Silico Studies to Support Vaccine Development. Pharmaceutics. 2023;15:654. doi: 10.3390/pharmaceutics15020654.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics15020654</ArticleId><ArticleId IdType="pmc">PMC9963741</ArticleId><ArticleId IdType="pubmed">36839975</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Trincado J.L., Gomez-Perosanz M., Reche P.A. Fundamentals and Methods for T- and B-Cell Epitope Prediction. J. Immunol. Res. 2017;2017:2680160. doi: 10.1155/2017/2680160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/2680160</ArticleId><ArticleId IdType="pmc">PMC5763123</ArticleId><ArticleId IdType="pubmed">29445754</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelmageed M.I., Abdelmoneim A.H., Mustafa M.I., Elfadol N.M., Murshed N.S., Shantier S.W., Makhawi A.M. Design of a Multiepitope-Based Peptide Vaccine against the e Protein of Human COVID-19: An Immunoinformatics Approach. Biomed Res. Int. 2020;2020:2683286. doi: 10.1155/2020/2683286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/2683286</ArticleId><ArticleId IdType="pmc">PMC7212276</ArticleId><ArticleId IdType="pubmed">32461973</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W., Joshi M.D., Singhania S., Ramsey K.H., Murthy A.K. Peptide vaccine: Progress and challenges. Vaccines. 2014;2:515–536. doi: 10.3390/vaccines2030515.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines2030515</ArticleId><ArticleId IdType="pmc">PMC4494216</ArticleId><ArticleId IdType="pubmed">26344743</ArticleId></ArticleIdList></Reference><Reference><Citation>Somogyi E., Csiszovszki Z., Molnár L., Lőrincz O., Tóth J., Pattijn S., Schockaert J., Mazy A., Miklós I., Pántya K., et al. A Peptide Vaccine Candidate Tailored to Individuals’ Genetics Mimics the Multi-Targeted T Cell Immunity of COVID-19 Convalescent Subjects. Front. Genet. 2021;12:684152. doi: 10.3389/fgene.2021.684152.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2021.684152</ArticleId><ArticleId IdType="pmc">PMC8261158</ArticleId><ArticleId IdType="pubmed">34249101</ArticleId></ArticleIdList></Reference><Reference><Citation>Farhani I., Yamchi A., Madanchi H., Khazaei V., Behrouzikhah M., Abbasi H., Salehi M., Moradi N., Sanami S. Designing a Multi-epitope Vaccine against the SARS-CoV-2 Variant based on an Immunoinformatics Approach. Curr. Comput. Aided. Drug Des. 2023;20:274–290. doi: 10.2174/1573409919666230612125440.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1573409919666230612125440</ArticleId><ArticleId IdType="pubmed">37309762</ArticleId></ArticleIdList></Reference><Reference><Citation>Rafi M.O., Al-Khafaji K., Sarker M.T., Taskin-Tok T., Rana A.S., Rahman M.S. Design of a multi-epitope vaccine against SARS-CoV-2: Immunoinformatic and computational methods. RSC Adv. 2022;12:4288–4310. doi: 10.1039/D1RA06532G.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/D1RA06532G</ArticleId><ArticleId IdType="pmc">PMC8981096</ArticleId><ArticleId IdType="pubmed">35425433</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamley I.W. Peptides for Vaccine Development. ACS Appl. Bio Mater. 2022;5:905–944. doi: 10.1021/acsabm.1c01238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsabm.1c01238</ArticleId><ArticleId IdType="pmc">PMC9384901</ArticleId><ArticleId IdType="pubmed">35195008</ArticleId></ArticleIdList></Reference><Reference><Citation>Grifoni A., Sidney J., Zhang Y., Scheuermann R.H., Peters B., Sette A. A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2. Cell Host Microbe. 2020;27:671–680.e2. doi: 10.1016/j.chom.2020.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.03.002</ArticleId><ArticleId IdType="pmc">PMC7142693</ArticleId><ArticleId IdType="pubmed">32183941</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin X., Liu X., Shen C. A systemic review of T-cell epitopes defined from the proteome of SARS-CoV-2. Virus Res. 2023;324:199024. doi: 10.1016/j.virusres.2022.199024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2022.199024</ArticleId><ArticleId IdType="pmc">PMC9757803</ArticleId><ArticleId IdType="pubmed">36526016</ArticleId></ArticleIdList></Reference><Reference><Citation>Kared H., Redd A.D., Bloch E.M., Bonny T.S., Sumatoh H., Kairi F., Carbajo D., Abel B., Newell E.W., Bettinotti M.P., et al. CD8+ T cell responses in convalescent COVID-19 individuals target epitopes from the entire SARS-CoV-2 proteome and show kinetics of early differentiation. bioRxiv. 2020 doi: 10.1101/2020.10.08.330688.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.10.08.330688</ArticleId></ArticleIdList></Reference><Reference><Citation>Prachar M., Justesen S., Steen-Jensen D.B., Thorgrimsen S., Jurgons E., Winther O., Bagger F.O. COVID-19 vaccine candidates: Prediction and validation of 174 SARS-CoV-2 Epitopes. bioRxiv. 2020 doi: 10.1101/2020.03.20.000794.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.03.20.000794</ArticleId><ArticleId IdType="pmc">PMC7686376</ArticleId><ArticleId IdType="pubmed">33235258</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezaei S., Sefidbakht Y., Uskoković V. Tracking the pipeline: Immunoinformatics and the COVID-19 vaccine design. Brief. Bioinform. 2021;22:bbab241. doi: 10.1093/bib/bbab241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bib/bbab241</ArticleId><ArticleId IdType="pubmed">34219142</ArticleId></ArticleIdList></Reference><Reference><Citation>Ochoa R., Lunardelli V.A.S., Rosa D.S., Laio A., Cossio P. Multiple-Allele MHC Class II Epitope Engineering by a Molecular Dynamics-Based Evolution Protocol. Front. Immunol. 2022;13:862851. doi: 10.3389/fimmu.2022.862851.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.862851</ArticleId><ArticleId IdType="pmc">PMC9094701</ArticleId><ArticleId IdType="pubmed">35572587</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirza M.U., Froeyen M. Structural elucidation of SARS-CoV-2 vital proteins: Computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase. J. Pharm. Anal. 2020;10:320–328. doi: 10.1016/j.jpha.2020.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpha.2020.04.008</ArticleId><ArticleId IdType="pmc">PMC7187848</ArticleId><ArticleId IdType="pubmed">32346490</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Gomez A., Pelaez-Prestel H.F., Juarez I. Approaches to evaluate the specific immune responses to SARS-CoV-2. Vaccine. 2023;41:6434–6443. doi: 10.1016/j.vaccine.2023.09.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.09.033</ArticleId><ArticleId IdType="pubmed">37770298</ArticleId></ArticleIdList></Reference><Reference><Citation>Villemonteix J., Cohen L., Guihot A., Guérin V., Moulin C., Caseris M., Carol A., Bonacorsi S., Carcelain G. Comparison between enzyme-linked immunospot assay and intracellular cytokine flow cytometry assays for the evaluation of T cell response to SARS-CoV-2 after symptomatic COVID-19. Immun. Inflamm. Dis. 2022;10:e617. doi: 10.1002/iid3.617.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.617</ArticleId><ArticleId IdType="pmc">PMC9449588</ArticleId><ArticleId IdType="pubmed">36169252</ArticleId></ArticleIdList></Reference><Reference><Citation>Holl E.K., Frazier V.N., Landa K., Beasley G.M., Hwang E.S., Nair S.K. Examining Peripheral and Tumor Cellular Immunome in Patients With Cancer. Front. Immunol. 2019;10:1767. doi: 10.3389/fimmu.2019.01767.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01767</ArticleId><ArticleId IdType="pmc">PMC6685102</ArticleId><ArticleId IdType="pubmed">31417550</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitoiset F., Cassard L., El Soufi K., Boselli L., Grivel J., Roux A., Klatzmann D., Chaput N., Rosenzwajg M. Deep phenotyping of immune cell populations by optimized and standardized flow cytometry analyses. Cytom. Part A. 2018;93:793–802. doi: 10.1002/cyto.a.23570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cyto.a.23570</ArticleId><ArticleId IdType="pubmed">30168890</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajab A., Axler O., Leung J., Wozniak M., Porwit A. Ten-color 15-antibody flow cytometry panel for immunophenotyping of lymphocyte population. Int. J. Lab. Hematol. 2017;39:76–85. doi: 10.1111/ijlh.12678.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijlh.12678</ArticleId><ArticleId IdType="pubmed">28447425</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxena A., Dagur P.K., Biancotto A. Multiparametric Flow Cytometry Analysis of Naïve, Memory, and Effector T Cells. Methods Mol. Biol. 2019;2032:129–140.</Citation><ArticleIdList><ArticleId IdType="pubmed">31522417</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagen M., Pangrazzi L., Rocamora-Reverte L., Weinberger B. Legend or Truth: Mature CD4+CD8+ Double-Positive T Cells in the Periphery in Health and Disease. Biomedicines. 2023;11:2702. doi: 10.3390/biomedicines11102702.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines11102702</ArticleId><ArticleId IdType="pmc">PMC10603952</ArticleId><ArticleId IdType="pubmed">37893076</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalpakci Y. Comparative evaluation of memory T cells in COVID-19 patients and the predictive role of CD4 + CD8 + double positive T lymphocytes as a new marker. Rev. Da Assoc. Médica Bras. 2020;66:1666–1672. doi: 10.1590/1806-9282.66.12.1666.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/1806-9282.66.12.1666</ArticleId><ArticleId IdType="pubmed">33331574</ArticleId></ArticleIdList></Reference><Reference><Citation>Velikkakam T. Negative T cells: Setting the stage for disease control or progression. Immunology. 2022;165:371–385. doi: 10.1111/imm.13441.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.13441</ArticleId><ArticleId IdType="pmc">PMC10626195</ArticleId><ArticleId IdType="pubmed">34939192</ArticleId></ArticleIdList></Reference><Reference><Citation>Mou Z., Liu D., Okwor I., Jia P., Orihara K., Uzonna J.E. MHC Class II Restricted Innate-Like Double Negative T Cells Contribute to Optimal Primary and Secondary Immunity to Leishmania major. PLoS Pathog. 2014;10:e1004396. doi: 10.1371/journal.ppat.1004396.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1004396</ArticleId><ArticleId IdType="pmc">PMC4169504</ArticleId><ArticleId IdType="pubmed">25233487</ArticleId></ArticleIdList></Reference><Reference><Citation>Beetz S., Marischen L., Kabelitz D., Wesch D. Human γδ T cells. Immunol. Res. 2007;37:97–111. doi: 10.1007/BF02685893.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02685893</ArticleId><ArticleId IdType="pubmed">17695246</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalyan S., Kabelitz D. Defining the nature of human γδ T cells: A biographical sketch of the highly empathetic. Cell. Mol. Immunol. 2013;10:21–29. doi: 10.1038/cmi.2012.44.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cmi.2012.44</ArticleId><ArticleId IdType="pmc">PMC4003173</ArticleId><ArticleId IdType="pubmed">23085947</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi C., Wang Y., Li P., Zhao J., Julia V. Gamma Delta T Cells and Their Pathogenic Role in Psoriasis. Front. Immunol. 2021;12:627139. doi: 10.3389/fimmu.2021.627139.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.627139</ArticleId><ArticleId IdType="pmc">PMC7959710</ArticleId><ArticleId IdType="pubmed">33732249</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Saihati H.A., Hussein H.A.M., Thabet A.A., Wardany A.A., Mahmoud S.Y., Farrag E.S., Mohamed T.I.A., Fathy S.M., Elnosary M.E., Sobhy A., et al. Memory T Cells Discrepancies in COVID-19 Patients. Microorganisms. 2023;11:2737. doi: 10.3390/microorganisms11112737.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms11112737</ArticleId><ArticleId IdType="pmc">PMC10673271</ArticleId><ArticleId IdType="pubmed">38004749</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathew D., Giles J.R., Baxter A.E., Oldridge D.A., Greenplate A.R., Wu J.E., Alanio C., Kuri-Cervantes L., Pampena M.B., D’Andrea K., et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science. 2020;369:eabc8511. doi: 10.1126/science.abc8511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc8511</ArticleId><ArticleId IdType="pmc">PMC7402624</ArticleId><ArticleId IdType="pubmed">32669297</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu C.F., Sabath F., Fibi-Smetana S., Sun S., Öllinger R., Noeßner E., Chao Y.Y., Rinke L., Winheim E., Rad R., et al. Convalescent COVID-19 Patients Without Comorbidities Display Similar Immunophenotypes Over Time Despite Divergent Disease Severities. Front. Immunol. 2021;12:601080. doi: 10.3389/fimmu.2021.601080.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.601080</ArticleId><ArticleId IdType="pmc">PMC8634761</ArticleId><ArticleId IdType="pubmed">34867933</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W., Zhou Y., Kang Y. Naïve T cells may be key to the low mortality of children with COVID-19. J. Evid. Based. Med. 2022;15:3–5. doi: 10.1111/jebm.12454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jebm.12454</ArticleId><ArticleId IdType="pubmed">35020980</ArticleId></ArticleIdList></Reference><Reference><Citation>Vazquez-Alejo E., Tarancon-Diez L., Espinar-Buitrago M.d.l.S., Genebat M., Calderón A., Pérez-Cabeza G., Magro-Lopez E., Leal M., Muñoz-Fernández M.Á. Persistent Exhausted T-Cell Immunity after Severe COVID-19: 6-Month Evaluation in a Prospective Observational Study. J. Clin. Med. 2023;12:3539. doi: 10.3390/jcm12103539.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12103539</ArticleId><ArticleId IdType="pmc">PMC10219183</ArticleId><ArticleId IdType="pubmed">37240647</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynisson B., Alvarez B., Paul S., Peters B., Nielsen M. NetMHCpan-4.1 and NetMHCIIpan-4.0: Improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 2021;48:W449–W454. doi: 10.1093/nar/gkaa379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkaa379</ArticleId><ArticleId IdType="pmc">PMC7319546</ArticleId><ArticleId IdType="pubmed">32406916</ArticleId></ArticleIdList></Reference><Reference><Citation>Stranzl T., Larsen M.V., Lundegaard C., Nielsen M. NetCTLpan: Pan-specific MHC class I pathway epitope predictions. Immunogenetics. 2010;62:357. doi: 10.1007/s00251-010-0441-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00251-010-0441-4</ArticleId><ArticleId IdType="pmc">PMC2875469</ArticleId><ArticleId IdType="pubmed">20379710</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin W., Sbai H., De Groot A.S. Bioinformatics tools for identifying class I-restricted epitopes. Methods. 2003;29:289–298. doi: 10.1016/S1046-2023(02)00351-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1046-2023(02)00351-1</ArticleId><ArticleId IdType="pubmed">12725794</ArticleId></ArticleIdList></Reference><Reference><Citation>Doytchinova I.A., Flower D.R. VaxiJen: A server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinform. 2007;8:1–7. doi: 10.1186/1471-2105-8-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-8-4</ArticleId><ArticleId IdType="pmc">PMC1780059</ArticleId><ArticleId IdType="pubmed">17207271</ArticleId></ArticleIdList></Reference><Reference><Citation>Macchia I., La Sorsa V., Ruspantini I., Sanchez M., Tirelli V., Carollo M., Fedele G., Leone P., Schiavoni G., Buccione C., et al. Multicentre Harmonisation of a Six-Colour Flow Cytometry Panel for Naïve/Memory T Cell Immunomonitoring. J. Immunol. Res. 2020;2020:1938704.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7153001</ArticleId><ArticleId IdType="pubmed">32322591</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamin C., Le Lann L., Alvarez-Errico D., Barbarroja N., Cantaert T., Ducreux J., Dufour A.M., Gerl V., Kniesch K., Neves E., et al. Multi-center harmonization of flow cytometers in the context of the European “PRECISESADS” project. Autoimmun. Rev. 2016;15:1038–1045. doi: 10.1016/j.autrev.2016.07.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2016.07.034</ArticleId><ArticleId IdType="pubmed">27490203</ArticleId></ArticleIdList></Reference><Reference><Citation>Streitz M., Miloud T., Kapinsky M., Reed M.R., Magari R., Geissler E.K., Hutchinson J.A., Vogt K., Schlickeiser S., Kverneland A.H., et al. Standardization of whole blood immune phenotype monitoring for clinical trials: Panels and methods from the ONE study. Transplant. Res. 2013;2:17. doi: 10.1186/2047-1440-2-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2047-1440-2-17</ArticleId><ArticleId IdType="pmc">PMC3827923</ArticleId><ArticleId IdType="pubmed">24160259</ArticleId></ArticleIdList></Reference><Reference><Citation>Borghi M., Gallinaro A., Pirillo M.F., Canitano A., Michelini Z., De Angelis M.L., Cecchetti S., Tinari A., Falce C., Mariotti S., et al. Different configurations of SARS-CoV-2 spike protein delivered by integrase-defective lentiviral vectors induce persistent functional immune responses, characterized by distinct immunogenicity profiles. Front. Immunol. 2023;14:1147953. doi: 10.3389/fimmu.2023.1147953.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1147953</ArticleId><ArticleId IdType="pmc">PMC10113491</ArticleId><ArticleId IdType="pubmed">37090707</ArticleId></ArticleIdList></Reference><Reference><Citation>Dispinseri S., Secchi M., Pirillo M.F., Tolazzi M., Borghi M., Brigatti C., De Angelis M.L., Baratella M., Bazzigaluppi E., Venturi G., et al. Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival. Nat. Commun. 2021;12:6–17. doi: 10.1038/s41467-021-22958-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-22958-8</ArticleId><ArticleId IdType="pmc">PMC8113594</ArticleId><ArticleId IdType="pubmed">33976165</ArticleId></ArticleIdList></Reference><Reference><Citation>Dispinseri S., Marzinotto I., Brigatti C., Pirillo M.F., Tolazzi M., Bazzigaluppi E., Canitano A., Borghi M., Gallinaro A., Caccia R., et al. Seasonal Betacoronavirus Antibodies’ Expansion Post-BNT161b2 Vaccination Associates with Reduced SARS-CoV-2 VoC Neutralization. J. Clin. Immunol. 2022;42:448–458. doi: 10.1007/s10875-021-01190-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-021-01190-5</ArticleId><ArticleId IdType="pmc">PMC8742681</ArticleId><ArticleId IdType="pubmed">35000058</ArticleId></ArticleIdList></Reference><Reference><Citation>Lê S., Josse J., Husson F. FactoMineR: An R package for multivariate analysis. J. Stat. Softw. 2008;25:1–18. doi: 10.18637/jss.v025.i01.</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v025.i01</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamura K., Stecher G., Kumar S. MEGA11: Molecular Evolutionary Genetics Analysis Version 11. Mol. Biol. Evol. 2021;38:3022–3027. doi: 10.1093/molbev/msab120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/molbev/msab120</ArticleId><ArticleId IdType="pmc">PMC8233496</ArticleId><ArticleId IdType="pubmed">33892491</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison P.W., Lopez R., Rahman N., Allen S.G., Aslam R., Buso N., Cummins C., Fathy Y., Felix E., Glont M., et al. The COVID-19 Data Portal: Accelerating SARS-CoV-2 and COVID-19 research through rapid open access data sharing. Nucleic Acids Res. 2021;49:W619–W623. doi: 10.1093/nar/gkab417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkab417</ArticleId><ArticleId IdType="pmc">PMC8218199</ArticleId><ArticleId IdType="pubmed">34048576</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannar D., Saville J.W., Zhu X., Srivastava S.S., Berezuk A.M., Zhou S. Structural analysis of receptor binding domain mutations in SARS-CoV-2 variants of concern that modulate ACE2 and antibody binding. Cell Rep. 2021;37:110156. doi: 10.1016/j.celrep.2021.110156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.110156</ArticleId><ArticleId IdType="pmc">PMC8642162</ArticleId><ArticleId IdType="pubmed">34914928</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurini E., Marson D., Aulic S., Fermeglia A., Pricl S. Molecular rationale for SARS-CoV-2 spike circulating mutations able to escape bamlanivimab and etesevimab monoclonal antibodies. Sci Rep. 2021;11:1–20. doi: 10.1038/s41598-021-99827-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-99827-3</ArticleId><ArticleId IdType="pmc">PMC8511038</ArticleId><ArticleId IdType="pubmed">34642465</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng B., Kemp S.A., Papa G., Datir R., Ferreira I.A.T.M., Marelli S. Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7. Cell Rep. 2021;35:109292. doi: 10.1016/j.celrep.2021.109292.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109292</ArticleId><ArticleId IdType="pmc">PMC8185188</ArticleId><ArticleId IdType="pubmed">34166617</ArticleId></ArticleIdList></Reference><Reference><Citation>Furusawa Y., Kiso M., Iida S., Uraki R., Hirata Y., Imai M. In SARS-CoV-2 delta variants, Spike-P681R and D950N promote membrane fusion, Spike-P681R enhances spike cleavage, but neither substitution affects pathogenicity in hamsters. eBioMedicine. 2023;91:104561. doi: 10.1016/j.ebiom.2023.104561.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2023.104561</ArticleId><ArticleId IdType="pmc">PMC10083686</ArticleId><ArticleId IdType="pubmed">37043872</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Jackson C.B., Mou H., Ojha A., Peng H., Quinlan B.D. SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat. Commun. 2020;11:1–9. doi: 10.1038/s41467-020-19808-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19808-4</ArticleId><ArticleId IdType="pmc">PMC7693302</ArticleId><ArticleId IdType="pubmed">33243994</ArticleId></ArticleIdList></Reference><Reference><Citation>Korber B., Fischer W.M., Gnanakaran S., Yoon H., Theiler J., Abfalterer W. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell. 2020;182:812–827.e19. doi: 10.1016/j.cell.2020.06.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.06.043</ArticleId><ArticleId IdType="pmc">PMC7332439</ArticleId><ArticleId IdType="pubmed">32697968</ArticleId></ArticleIdList></Reference><Reference><Citation>Plante J.A., Liu Y., Liu J., Xia H., Johnson B.A., Lokugamage K.G. Spike mutation D614G alters SARS-CoV-2 fitness. Nature. 2021;592:116–121. doi: 10.1038/s41586-020-2895-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2895-3</ArticleId><ArticleId IdType="pmc">PMC8158177</ArticleId><ArticleId IdType="pubmed">33106671</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Deng S., Ren L., Zheng P., Hu X., Jin T., Tan X. Profiling CD8+ T cell epitopes of COVID-19 convalescents reveals reduced cellular immune responses to SARS-CoV-2 variants. Cell Rep. 2021;36:109708. doi: 10.1016/j.celrep.2021.109708.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109708</ArticleId><ArticleId IdType="pmc">PMC8390359</ArticleId><ArticleId IdType="pubmed">34506741</ArticleId></ArticleIdList></Reference><Reference><Citation>Shomuradova A.S., Vagida M.S., Sheetikov S.A., Zornikova K.V., Kiryukhin D., Titov A., Peshkova I.O., Khmelevskaya A., Dianov D.V., Malasheva M., et al. SARS-CoV-2 Epitopes Are Recognized by a Public and Diverse Repertoire of Human T Cell Receptors. Immunity. 2020;53:1245–1257.e5. doi: 10.1016/j.immuni.2020.11.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.11.004</ArticleId><ArticleId IdType="pmc">PMC7664363</ArticleId><ArticleId IdType="pubmed">33326767</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao F., Mallajoysula V., Arunachalam P.S., van der Ploeg K., Manohar M., Röltgen K., Yang F., Wirz O., Hoh R., Haraguchi E., et al. Spheromers reveal robust T cell responses to the Pfizer/BioNTech vaccine and attenuated peripheral CD8+ T cell responses post SARS-CoV-2 infection. Immunity. 2023;56:864–878.e4. doi: 10.1016/j.immuni.2023.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2023.03.005</ArticleId><ArticleId IdType="pmc">PMC10017386</ArticleId><ArticleId IdType="pubmed">36996809</ArticleId></ArticleIdList></Reference><Reference><Citation>Saini S.K., Hersby D.S., Tamhane T., Povlsen H.R., Amaya Hernandez S.P., Nielsen M., Gang A.O., Hadrup S.R. SARS-CoV-2 genome-wide T cell epitope mapping reveals immunodominance and substantial CD8+ T cell activation in COVID-19 patients. Sci. Immunol. 2021;6:eabf7550. doi: 10.1126/sciimmunol.abf7550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abf7550</ArticleId><ArticleId IdType="pmc">PMC8139428</ArticleId><ArticleId IdType="pubmed">33853928</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallajosyula V., Ganjavi C., Chakraborty S., McSween A.M., Pavlovitch-Bedzyk A.J., Wilhelmy J., Nau A., Manohar M., Nadeau K.C., Davis M.M. CD8+T cells specific for conserved coronavirus epitopes correlate with milder disease in COVID-19 patients. Sci. Immunol. 2021;6:eabg5669. doi: 10.1126/sciimmunol.abg5669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abg5669</ArticleId><ArticleId IdType="pmc">PMC8975171</ArticleId><ArticleId IdType="pubmed">34210785</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu C., Shen M., Han X., Chen Q., Li L., Chen S., Zhang J., Gao F., Wang W., Wang Y., et al. Identification of cross-reactive CD8+ T cell receptors with high functional avidity to a SARS-CoV-2 immunodominant epitope and its natural mutant variants. Genes Dis. 2022;9:216–229. doi: 10.1016/j.gendis.2021.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gendis.2021.05.006</ArticleId><ArticleId IdType="pmc">PMC8240504</ArticleId><ArticleId IdType="pubmed">34222571</ArticleId></ArticleIdList></Reference><Reference><Citation>Gfeller D., Schmidt J., Croce G., Guillaume P., Bobisse S., Genolet R., Queiroz L., Cesbron J., Racle J., Harari A. Improved predictions of antigen presentation and TCR recognition with MixMHCpred2.2 and PRIME2.0 reveal potent SARS-CoV-2 CD8+ T-cell epitopes. Cell Syst. 2023;14:72–83.e5. doi: 10.1016/j.cels.2022.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cels.2022.12.002</ArticleId><ArticleId IdType="pmc">PMC9811684</ArticleId><ArticleId IdType="pubmed">36603583</ArticleId></ArticleIdList></Reference><Reference><Citation>Agerer B., Koblischke M., Gudipati V., Montaño-Gutierrez L.F., Smyth M., Popa A., Genger J.W., Endler L., Florian D.M., Mühlgrabner V., et al. SARS-CoV-2 mutations in MHC-I-restricted epitopes evade CD8+ T cell responses. Sci. Immunol. 2021;6:17–22. doi: 10.1126/sciimmunol.abg6461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abg6461</ArticleId><ArticleId IdType="pmc">PMC8224398</ArticleId><ArticleId IdType="pubmed">33664060</ArticleId></ArticleIdList></Reference><Reference><Citation>Proietto D., Dallan B., Gallerani E., Albanese V., Llewellyn-Lacey S., Price D.A., Appay V., Pacifico S., Caputo A., Nicoli F., et al. Ageing Curtails the Diversity and Functionality of Nascent CD8+ T Cell Responses against SARS-CoV-2. Vaccines. 2023;11:154. doi: 10.3390/vaccines11010154.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11010154</ArticleId><ArticleId IdType="pmc">PMC9867380</ArticleId><ArticleId IdType="pubmed">36679999</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner K.I., Mateyka L.M., Jarosch S., Grass V., Weber S., Schober K., Hammel M., Burrell T., Kalali B., Poppert H., et al. Recruitment of highly cytotoxic CD8+ T cell receptors in mild SARS-CoV-2 infection. Cell Rep. 2022;38:110214. doi: 10.1016/j.celrep.2021.110214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.110214</ArticleId><ArticleId IdType="pmc">PMC8677487</ArticleId><ArticleId IdType="pubmed">34968416</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin X., Ding Y., Sun S., Wang X., Zhou Z., Liu X., Li M., Chen X., Shen A., Wu Y., et al. Screening HLA-A-restricted T cell epitopes of SARS-CoV-2 and the induction of CD8+ T cell responses in HLA-A transgenic mice. Cell. Mol. Immunol. 2021;18:2588–2608. doi: 10.1038/s41423-021-00784-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-021-00784-8</ArticleId><ArticleId IdType="pmc">PMC8561351</ArticleId><ArticleId IdType="pubmed">34728796</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu C., Xiao C., Wang Z., Zhu G., Mao L., Chen X., Gao L., Deng J., Su J., Su H., et al. CD8+ T-Cell Epitope Variations Suggest a Potential Antigen HLA-A2 Binding Deficiency for Spike Protein of SARS-CoV-2. Front. Immunol. 2022;12:764949. doi: 10.3389/fimmu.2021.764949.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.764949</ArticleId><ArticleId IdType="pmc">PMC8804355</ArticleId><ArticleId IdType="pubmed">35116022</ArticleId></ArticleIdList></Reference><Reference><Citation>Kared H., Redd A.D., Bloch E.M., Bonny T.S., Sumatoh H., Kairi F., Carbajo D., Abel B., Newell E.W., Bettinotti M.P., et al. SARS-CoV-2-specific CD8+ T cell responses in convalescent COVID-19 individuals. J. Clin. Investig. 2021;131:e141576. doi: 10.1172/JCI145476.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI145476</ArticleId><ArticleId IdType="pmc">PMC7919723</ArticleId><ArticleId IdType="pubmed">33427749</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao C., Ren Z., Zhang B., Mao L., Zhu G., Gao L., Su J., Ye J., Long Z., Zhu Y., et al. Insufficient epitope-specific T cell clones are responsible for impaired cellular immunity to inactivated SARS-CoV-2 vaccine in older adults. Nat. Aging. 2023;3:418–435. doi: 10.1038/s43587-023-00379-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43587-023-00379-0</ArticleId><ArticleId IdType="pmc">PMC10154213</ArticleId><ArticleId IdType="pubmed">37117789</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao C., Mao L., Wang Z., Gao L., Zhu G., Su J., Chen X., Yuan J., Hu Y., Yin Z., et al. SARS-CoV-2 variant B.1.1.7 caused HLA-A2+ CD8+ T cell epitope mutations for impaired cellular immune response. iScience. 2022;25:103934. doi: 10.1016/j.isci.2022.103934.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2022.103934</ArticleId><ArticleId IdType="pmc">PMC8851741</ArticleId><ArticleId IdType="pubmed">35194575</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng J., Pan J., Qiu M., Mao L., Wang Z., Zhu G., Gao L., Su J., Hu Y., Luo O.J., et al. Identification of HLA-A2 restricted CD8+ T cell epitopes in SARS-CoV-2 structural proteins. J. Leukoc. Biol. 2021;110:1171–1180. doi: 10.1002/JLB.4MA0621-020R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JLB.4MA0621-020R</ArticleId><ArticleId IdType="pmc">PMC9290883</ArticleId><ArticleId IdType="pubmed">34231935</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis J.M., Leistritz-Edwards D., Dunn A., Tarr C., Lehman J., Dempsey C., Hamel A., Rayon V., Liu G., Wang Y., et al. Allelic variation in class I HLA determines CD8+ T cell repertoire shape and cross-reactive memory responses to SARS-CoV-2. Sci. Immunol. 2022;3070:eabk3070.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9017864</ArticleId><ArticleId IdType="pubmed">34793243</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarke A., Sidney J., Kidd C.K., Dan J.M., Ramirez S.I., Yu E.D., Mateus J., da Silva Antunes R., Moore E., Rubiro P., et al. Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. Cell Reports Med. 2021;2:100204. doi: 10.1016/j.xcrm.2021.100204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100204</ArticleId><ArticleId IdType="pmc">PMC7837622</ArticleId><ArticleId IdType="pubmed">33521695</ArticleId></ArticleIdList></Reference><Reference><Citation>Poran A., Harjanto D., Malloy M., Arieta C.M., Rothenberg D.A., Lenkala D., Van Buuren M.M., Addona T.A., Rooney M.S., Srinivasan L., et al. Sequence-based prediction of SARS-CoV-2 vaccine targets using a mass spectrometry-based bioinformatics predictor identifies immunogenic T cell epitopes. Genome Med. 2020;12:1–15. doi: 10.1186/s13073-020-00767-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13073-020-00767-w</ArticleId><ArticleId IdType="pmc">PMC7425796</ArticleId><ArticleId IdType="pubmed">32791978</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratishvili T., Quach H.Q., Haralambieva I.H., Suryawanshi Y.R., Ovsyannikova I.G., Kennedy R.B., Poland G.A. A multifaceted approach for identification, validation, and immunogenicity of naturally processed and in silico-predicted highly conserved SARS-CoV-2 peptides. Vaccine. 2024;42:162–174. doi: 10.1016/j.vaccine.2023.12.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.12.024</ArticleId><ArticleId IdType="pubmed">38105139</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen A.R., Jin X.X., Tang T.T., Ding Y., Liu X.T., Zhong X., Wu Y.D., Han X.L., Zhao G.Y., Shen C.L., et al. Exosomal Vaccine Loading T Cell Epitope Peptides of SARS-CoV-2 Induces Robust CD8+ T Cell Response in HLA-A Transgenic Mice. Int. J. Nanomedicine. 2022;17:3325–3341. doi: 10.2147/IJN.S367494.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/IJN.S367494</ArticleId><ArticleId IdType="pmc">PMC9346304</ArticleId><ArticleId IdType="pubmed">35937077</ArticleId></ArticleIdList></Reference><Reference><Citation>Chour W., Choi J., Xie J., Chaffee M.E., Schmitt T.M., Finton K., DeLucia D.C., Xu A.M., Su Y., Chen D.G., et al. Large libraries of single-chain trimer peptide-MHCs enable antigen-specific CD8+ T cell discovery and analysis. Commun. Biol. 2023;6:528. doi: 10.1038/s42003-023-04899-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-023-04899-8</ArticleId><ArticleId IdType="pmc">PMC10186326</ArticleId><ArticleId IdType="pubmed">37193826</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyder T.M., Gittelman R.M., Klinger M., May D.H., Osborne E.J., Taniguchi R., Zahid H.J., Kaplan I.M., Dines J.N., Noakes M.T., et al. Magnitude and Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population Levels. medRxiv. 2020 doi: 10.1101/2020.07.31.20165647.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.07.31.20165647</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang-Meli J., Luxenburger H., Wild K., Karl V., Oberhardt V., Salimi Alizei E., Graeser A., Reinscheid M., Roehlen N., Reeg D.B., et al. SARS-CoV-2-specific T-cell epitope repertoire in convalescent and mRNA-vaccinated individuals. Nat. Microbiol. 2022;7:675–679. doi: 10.1038/s41564-022-01106-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-022-01106-y</ArticleId><ArticleId IdType="pmc">PMC9064790</ArticleId><ArticleId IdType="pubmed">35484232</ArticleId></ArticleIdList></Reference><Reference><Citation>Lie-Andersen O., Hübbe M.L., Subramaniam K., Steen-Jensen D., Bergmann A.C., Justesen D., Holmström M.O., Turtle L., Justesen S., Lança T., et al. Impact of peptide: HLA complex stability for the identification of SARS-CoV-2-specific CD8+T cells. Front. Immunol. 2023;14:1151659. doi: 10.3389/fimmu.2023.1151659.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1151659</ArticleId><ArticleId IdType="pmc">PMC10232890</ArticleId><ArticleId IdType="pubmed">37275886</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan K., Chiu Y., Huang E., Chen M., Wang J., Lai I., Singh S., Shaw R.M., MacCoss M.J., Yee C. Mass spectrometric identification of immunogenic SARS-CoV-2 epitopes and cognate TCRs. Proc. Natl. Acad. Sci. USA. 2021;118:e2111815118. doi: 10.1073/pnas.2111815118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2111815118</ArticleId><ArticleId IdType="pmc">PMC8609653</ArticleId><ArticleId IdType="pubmed">34725257</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelde A., Bilich T., Heitmann J.S., Maringer Y., Salih H.R., Roerden M., Lübke M., Bauer J., Rieth J., Wacker M., et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. Nat. Immunol. 2020;22:74–85. doi: 10.1038/s41590-020-00808-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-00808-x</ArticleId><ArticleId IdType="pubmed">32999467</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekine T., Perez-Potti A., Rivera-Ballesteros O., Strålin K., Gorin J.B., Olsson A., Llewellyn-Lacey S., Kamal H., Bogdanovic G., Muschiol S., et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020;183:158–168.e14. doi: 10.1016/j.cell.2020.08.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.08.017</ArticleId><ArticleId IdType="pmc">PMC7427556</ArticleId><ArticleId IdType="pubmed">32979941</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Dijssel J., Hagen R.R., de Jongh R., Steenhuis M., Rispens T., Geerdes D.M., Mok J.Y., Kragten A.H.M., Duurland M.C., Verstegen N.J.M., et al. Parallel detection of SARS-CoV-2 epitopes reveals dynamic immunodominance profiles of CD8+ T memory cells in convalescent COVID-19 donors. Clin. Transl. Immunol. 2022;11:e1423. doi: 10.1002/cti2.1423.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cti2.1423</ArticleId><ArticleId IdType="pmc">PMC9568370</ArticleId><ArticleId IdType="pubmed">36254196</ArticleId></ArticleIdList></Reference><Reference><Citation>Duette G., Lee E., Martins Costa Gomes G., Tungatt K., Doyle C., Stylianou V.V., Lee A., Maddocks S., Taylor J., Khanna R., et al. Highly Networked SARS-CoV-2 Peptides Elicit T Cell Responses with Enhanced Specificity. ImmunoHorizons. 2023;7:508–527. doi: 10.4049/immunohorizons.2300034.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/immunohorizons.2300034</ArticleId><ArticleId IdType="pmc">PMC10580120</ArticleId><ArticleId IdType="pubmed">37358499</ArticleId></ArticleIdList></Reference><Reference><Citation>Takagi A., Matsui M. Identification of HLA-A*02:01-Restricted Candidate Epitopes Derived from the Nonstructural Polyprotein 1a of SARS-CoV-2 That May Be Natural Targets of CD8 + T Cell Recognition In Vivo. J. Virol. 2021;95:1837–1857. doi: 10.1128/JVI.01837-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01837-20</ArticleId><ArticleId IdType="pmc">PMC8092843</ArticleId><ArticleId IdType="pubmed">33268522</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohyama S., Ohno S., Suda T., Taneichi M., Yokoyama S., Mori M., Kobayashi A., Hayashi H., Uchida T., Matsui M. Efficient induction of cytotoxic T lymphocytes specific for severe acute respiratory syndrome (SARS)-associated coronavirus by immunization with surface-linked liposomal peptides derived from a non-structural polyprotein 1a. Antiviral Res. 2009;84:168–177. doi: 10.1016/j.antiviral.2009.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2009.09.004</ArticleId><ArticleId IdType="pmc">PMC7114085</ArticleId><ArticleId IdType="pubmed">19748524</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulien I., Kemming J., Oberhardt V., Wild K., Seidel L.M., Killmer S., Sagar, Daul F., Salvat Lago M., Decker A., et al. Characterization of pre-existing and induced SARS-CoV-2-specific CD8+ T cells. Nat. Med. 2021;27:78–85. doi: 10.1038/s41591-020-01143-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-01143-2</ArticleId><ArticleId IdType="pubmed">33184509</ArticleId></ArticleIdList></Reference><Reference><Citation>Habel J.R., Nguyen T.H.O., van de Sandt C.E., Juno J.A., Chaurasia P., Wragg K., Koutsakos M., Hensen L., Jia X., Chua B., et al. Suboptimal SARS-CoV-2−specific CD8+ T cell response associated with the prominent HLA-A*02:01 phenotype. Proc. Natl. Acad. Sci. USA. 2020;117:24384–24391. doi: 10.1073/pnas.2015486117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2015486117</ArticleId><ArticleId IdType="pmc">PMC7533701</ArticleId><ArticleId IdType="pubmed">32913053</ArticleId></ArticleIdList></Reference><Reference><Citation>Rammensee H.G., Bachmann J., Emmerich N.P.N., Bachor O.A., Stevanović S. SYFPEITHI: Database for MHC ligands and peptide motifs. Immunogenet. 1999;50:213–219. doi: 10.1007/s002510050595.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s002510050595</ArticleId><ArticleId IdType="pubmed">10602881</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra T., Dalavi R., Joshi G., Kumar A., Pandey P., Shukla S., Mishra R.K., Chande A. SARS-CoV-2 spike E156G/Δ157-158 mutations contribute to increased infectivity and immune escape. Life Sci. Alliance. 2022;5:1415. doi: 10.26508/lsa.202201415.</Citation><ArticleIdList><ArticleId IdType="doi">10.26508/lsa.202201415</ArticleId><ArticleId IdType="pmc">PMC8927725</ArticleId><ArticleId IdType="pubmed">35296517</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhari A.M., Joshi M., Kumar D., Patel A., Lokhande K.B., Krishnan A. Evaluation of immune evasion in SARS-CoV-2 Delta and Omicron variants. Comput. Struct. Biotechnol. J. 2022;20:4501–4516. doi: 10.1016/j.csbj.2022.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csbj.2022.08.010</ArticleId><ArticleId IdType="pmc">PMC9359593</ArticleId><ArticleId IdType="pubmed">35965661</ArticleId></ArticleIdList></Reference><Reference><Citation>McCallum M., Walls A.C., Sprouse K.R., Bowen J.E., Rosen L.E., Dang H.V. Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants. Science. 2021;374:1621–1626. doi: 10.1126/science.abl8506.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abl8506</ArticleId><ArticleId IdType="pubmed">34751595</ArticleId></ArticleIdList></Reference><Reference><Citation>Nersisyan S., Zhiyanov A., Zakharova M., Ishina I., Kurbatskaia I., Mamedov A. Alterations in SARS-CoV-2 Omicron and Delta peptides presentation by HLA molecules. PeerJ. 2022;10:1–15. doi: 10.7717/peerj.13354.</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj.13354</ArticleId><ArticleId IdType="pmc">PMC9055995</ArticleId><ArticleId IdType="pubmed">35502206</ArticleId></ArticleIdList></Reference><Reference><Citation>Soni M.K., Migliori E., Fu J., Assal A., Chan H.T., Pan J., Khatiwada P., Ciubotariu R., May M.S., Pereira M.R., et al. The prospect of universal coronavirus immunity: Characterization of reciprocal and non-reciprocal T cell responses against SARS-CoV2 and common human coronaviruses. Front. Immunol. 2023;14:1212203. doi: 10.3389/fimmu.2023.1212203.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1212203</ArticleId><ArticleId IdType="pmc">PMC10612330</ArticleId><ArticleId IdType="pubmed">37901229</ArticleId></ArticleIdList></Reference><Reference><Citation>Sallusto F., Lenig D., Forster R., Lipp M., Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials. Nature. 1999;401:709–712. doi: 10.1038/44385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/44385</ArticleId><ArticleId IdType="pubmed">10537110</ArticleId></ArticleIdList></Reference><Reference><Citation>Sallusto F., Geginat J., Lanzavecchia A. Central memory and effector memory T cell subsets: Function, Generation, and Maintenance. Annu. Rev. Immunol. 2004;22:745–763. doi: 10.1146/annurev.immunol.22.012703.104702.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.22.012703.104702</ArticleId><ArticleId IdType="pubmed">15032595</ArticleId></ArticleIdList></Reference><Reference><Citation>Alibakhshi A., Bahrami A.A. In-silico design of a new multi-epitope vaccine candidate against SARS-CoV-2. Acta Virol. 2024;2024:12481. doi: 10.3389/av.2023.12481.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/av.2023.12481</ArticleId></ArticleIdList></Reference><Reference><Citation>Piadel K., Haybatollahi A., Dalgleish A.G., Smith P.L. Selection and T-cell antigenicity of synthetic long peptides derived from SARS-CoV-2. J. Gen. Virol. 2022;103:001698. doi: 10.1099/jgv.0.001698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.001698</ArticleId><ArticleId IdType="pmc">PMC8895615</ArticleId><ArticleId IdType="pubmed">35014605</ArticleId></ArticleIdList></Reference><Reference><Citation>Tirziu A., Paunescu V. Cytotoxic T-Cell-Based Vaccine against SARS-CoV-2: A Hybrid Immunoinformatic Approach. Vaccines. 2022;10:218. doi: 10.3390/vaccines10020218.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10020218</ArticleId><ArticleId IdType="pmc">PMC8878688</ArticleId><ArticleId IdType="pubmed">35214676</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitiriga V.C., Papamentzelopoulou M., Konstantinakou K.E., Theodoridou K. SARS-CoV-2 T Cell Immunity Responses following Natural Infection and Vaccination. Vaccines. 2023;11:1186. doi: 10.3390/vaccines11071186.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11071186</ArticleId><ArticleId IdType="pmc">PMC10384199</ArticleId><ArticleId IdType="pubmed">37515000</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava K., Carreño J.M., Gleason C., Monahan B., Singh G., Abbad A., Tcheou J., Raskin A., Kleiner G., van Bakel H., et al. SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase. Immunity. 2024;57:587–599.e4. doi: 10.1016/j.immuni.2024.01.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2024.01.017</ArticleId><ArticleId IdType="pmc">PMC11066813</ArticleId><ArticleId IdType="pubmed">38395697</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Shea K., Schuler C., Gherasim C., Manthei D., Chen J., Zettel C., Troost J., Kennedy A., Tai A., Giacherio D., et al. Vaccination against COVID-19 Leads to Enhanced Immunity Despite Infection History. J. Allergy Clin. Immunol. 2022;149:AB96. doi: 10.1016/j.jaci.2021.12.338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2021.12.338</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradenas E., Ubals M., Urrea V., Suñer C., Trinité B., Riveira-Muñoz E., Marfil S., Ávila-Nieto C., Rodríguez de la Concepción M.L., Tarrés-Freixas F., et al. Virological and Clinical Determinants of the Magnitude of Humoral Responses to SARS-CoV-2 in Mild-Symptomatic Individuals. Front. Immunol. 2022;13:860215. doi: 10.3389/fimmu.2022.860215.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.860215</ArticleId><ArticleId IdType="pmc">PMC9097229</ArticleId><ArticleId IdType="pubmed">35572570</ArticleId></ArticleIdList></Reference><Reference><Citation>Servian C.d.P., Spadafora-Ferreira M., Dos Anjos D.C.C., Guilarde A.O., Gomes-Junior A.R., Borges M.A.S.B., Masson L.C., Silva J.M.M., de Lima M.H.A., Moraes B.G.N., et al. Distinct anti-NP, anti-RBD and anti-Spike antibody profiles discriminate death from survival in COVID-19. Front. Immunol. 2023;14:1206979. doi: 10.3389/fimmu.2023.1206979.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1206979</ArticleId><ArticleId IdType="pmc">PMC10591157</ArticleId><ArticleId IdType="pubmed">37876932</ArticleId></ArticleIdList></Reference><Reference><Citation>Pallett S.J.C., Jones R., Abdulaal A., Pallett M.A., Rayment M., Patel A., Denny S.J., Mughal N., Khan M., de Oliveira C.R., et al. Variability in detection of SARS-CoV-2-specific antibody responses following mild infection: A prospective multicentre cross-sectional study, London, United Kingdom, 17 April to 17 July 2020. Eurosurveillance. 2022;27:2002076. doi: 10.2807/1560-7917.ES.2022.27.4.2002076.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2022.27.4.2002076</ArticleId><ArticleId IdType="pmc">PMC8796290</ArticleId><ArticleId IdType="pubmed">35086612</ArticleId></ArticleIdList></Reference><Reference><Citation>Movsisyan M., Chopikyan A., Kasparova I., Hakobjanyan G., Carrat F., Sukiasyan M., Rushanyan M., Chalabyan M., Shariff S., Kantawala B., et al. Kinetics of anti-nucleocapsid IgG response in COVID-19 immunocompetent convalescent patients. Sci. Rep. 2022;12:12403. doi: 10.1038/s41598-022-16402-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-16402-0</ArticleId><ArticleId IdType="pmc">PMC9297274</ArticleId><ArticleId IdType="pubmed">35859108</ArticleId></ArticleIdList></Reference><Reference><Citation>Abebe E.C., Dejenie T.A. Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications. Front. Immunol. 2023;14:1055457. doi: 10.3389/fimmu.2023.1055457.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1055457</ArticleId><ArticleId IdType="pmc">PMC9892939</ArticleId><ArticleId IdType="pubmed">36742320</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkcaldy R.D., King B.A. COVID-19 and Postinfection Immunity Limited Evidence, Many Remaining Questions. JAMA. 2024;323:5–6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8596300</ArticleId><ArticleId IdType="pubmed">32391855</ArticleId></ArticleIdList></Reference><Reference><Citation>Tegeler C.M., Bilich T., Maringer Y., Salih H.R. Prevalence of COVID-19-associated symptoms during acute infection in relation to SARS-CoV-2-directed humoral and cellular immune responses in a mild-diseased convalescent cohort. Int. J. Infect. Dis. 2022;120:187–195. doi: 10.1016/j.ijid.2022.04.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2022.04.019</ArticleId><ArticleId IdType="pmc">PMC9007751</ArticleId><ArticleId IdType="pubmed">35429640</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham M.S., Sudre C.H., May A., Antonelli M., Murray B., Varsavsky T., Kläser K., Canas L.S., Molteni E., Modat M., et al. Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: An ecological study. Lancet Public Health. 2021;6:e335–e345. doi: 10.1016/S2468-2667(21)00055-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-2667(21)00055-4</ArticleId><ArticleId IdType="pmc">PMC8041365</ArticleId><ArticleId IdType="pubmed">33857453</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni C., Valdes A.M., Polidori L., Antonelli M., Penamakuri S., Nogal A., Louca P., May A., Figueiredo J.C., Hu C., et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: A prospective observational study from the ZOE COVID Study. Lancet. 2022;399:1618–1624. doi: 10.1016/S0140-6736(22)00327-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00327-0</ArticleId><ArticleId IdType="pmc">PMC8989396</ArticleId><ArticleId IdType="pubmed">35397851</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker M., Elliott J., Bodinier B., Barclay W., Ward H., Cooke G., Donnelly C.A., Chadeau-Hyam M., Elliott P. Variant-specific symptoms of COVID-19 in a study of 1,542,510 adults in England. Nat. Commun. 2022;13:6856. doi: 10.1038/s41467-022-34244-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-34244-2</ArticleId><ArticleId IdType="pmc">PMC9651890</ArticleId><ArticleId IdType="pubmed">36369151</ArticleId></ArticleIdList></Reference><Reference><Citation>Tavakol Z., Ghannadi S., Tabesh M.R., Halabchi F., Noormohammadpour P., Akbarpour S., Alizadeh Z., Nezhad M.H., Reyhan S.K. Relationship between physical activity, healthy lifestyle and COVID-19 disease severity; a cross-sectional study. J. Public Health. 2023;31:267–275. doi: 10.1007/s10389-020-01468-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10389-020-01468-9</ArticleId><ArticleId IdType="pmc">PMC7858040</ArticleId><ArticleId IdType="pubmed">33558839</ArticleId></ArticleIdList></Reference><Reference><Citation>Takács J., Deák D., Koller A. Higher level of physical activity reduces mental and neurological symptoms during and two years after COVID-19 infection in young women. Sci. Rep. 2024;14:6927. doi: 10.1038/s41598-024-57646-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-57646-2</ArticleId><ArticleId IdType="pmc">PMC10960016</ArticleId><ArticleId IdType="pubmed">38519586</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucholc M., Bradley D., Bennett D., Patterson L., Spiers R., Gibson D., Van Woerden H., Bjourson A.J. Identifying pre-existing conditions and multimorbidity patterns associated with in-hospital mortality in patients with COVID-19. Sci. Rep. 2022;12:17313. doi: 10.1038/s41598-022-20176-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-20176-w</ArticleId><ArticleId IdType="pmc">PMC9568958</ArticleId><ArticleId IdType="pubmed">36243878</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell C.D., Lone N.I., Baillie J.K. Comorbidities, multimorbidity and COVID-19. Nat. Med. 2023;29:334–343. doi: 10.1038/s41591-022-02156-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02156-9</ArticleId><ArticleId IdType="pubmed">36797482</ArticleId></ArticleIdList></Reference><Reference><Citation>Peña Rodríguez M., Hernández Bello J., Vega Magaña N., Viera Segura O., García Chagollán M., Ceja Gálvez H.R., Mora Mora J.C., Rentería Flores F.I., García González O.P., Muñoz Valle J.F. Prevalence of symptoms, comorbidities, and reinfections in individuals infected with Wild-Type SARS-CoV-2, Delta, or Omicron variants: A comparative study in western Mexico. Front. Public Health. 2023;11:1149795. doi: 10.3389/fpubh.2023.1149795.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2023.1149795</ArticleId><ArticleId IdType="pmc">PMC10174068</ArticleId><ArticleId IdType="pubmed">37181688</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinott E., Kozer E., Shapira Y., Bar-Haim A., Youngster I. Ibuprofen use and clinical outcomes in COVID-19 patients. Clin. Microbiol. Infect. 2020;26:1259.e5–1259.e7. doi: 10.1016/j.cmi.2020.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.06.003</ArticleId><ArticleId IdType="pmc">PMC7289730</ArticleId><ArticleId IdType="pubmed">32535147</ArticleId></ArticleIdList></Reference><Reference><Citation>Leal N.S., Yu Y., Chen Y., Fedele G., Martins L.M. Paracetamol Is Associated with a Lower Risk of COVID-19 Infection and Decreased ACE2 Protein Expression: A Retrospective Analysis. Covid. 2021;1:218–229. doi: 10.3390/covid1010018.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/covid1010018</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultze-Florey C.R., Chukhno E., Goudeva L., Blasczyk R., Ganser A., Prinz I., Förster R., Koenecke C., Odak I. Distribution of major lymphocyte subsets and memory T-cell subpopulations in healthy adults employing GLP-conforming multicolor flow cytometry. Leukemia. 2021;35:3021–3025. doi: 10.1038/s41375-021-01348-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41375-021-01348-5</ArticleId><ArticleId IdType="pmc">PMC8478656</ArticleId><ArticleId IdType="pubmed">34290358</ArticleId></ArticleIdList></Reference><Reference><Citation>Criado I., Nieto W.G., Oliva-Ariza G., Fuentes-Herrero B., Teodosio C., Lecrevisse Q., Lopez A., Romero A., Almeida J., Orfao A. Age- and Sex-Matched Normal Leukocyte Subset Ranges in the General Population Defined with the EuroFlow Lymphocyte Screening Tube (LST) for Monoclonal B-Cell Lymphocytosis (MBL) vs. Non-MBL Subjects. Cancers. 2022;15:58. doi: 10.3390/cancers15010058.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers15010058</ArticleId><ArticleId IdType="pmc">PMC9817826</ArticleId><ArticleId IdType="pubmed">36612056</ArticleId></ArticleIdList></Reference><Reference><Citation>Starke K.R., Reissig D., Petereit-Haack G., Schmauder S., Nienhaus A., Seidler A. The isolated effect of age on the risk of COVID-19 severe outcomes: A systematic review with meta-analysis. BMJ Glob. Health. 2021;6:e006434. doi: 10.1136/bmjgh-2021-006434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2021-006434</ArticleId><ArticleId IdType="pmc">PMC8678541</ArticleId><ArticleId IdType="pubmed">34916273</ArticleId></ArticleIdList></Reference><Reference><Citation>Yek C., Warner S., Wiltz J.L., Sun J., Adjei S., Mancera A., Silk B.J., Gundlapalli A.V., Harris A.M., Boehmer T.K., et al. Risk Factors for Severe COVID-19 Outcomes Among Persons Aged ≥18 Years Who Completed a Primary COVID-19 Vaccination Series—465 Health Care Facilities, United States, December 2020–October 2021. MMWR Morb. Mortal. Wkly. Rep. 2022;71:19–25. doi: 10.15585/mmwr.mm7101a4.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7101a4</ArticleId><ArticleId IdType="pmc">PMC8735560</ArticleId><ArticleId IdType="pubmed">34990440</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciarambino T., Crispino P., Minervini G., Giordano M. COVID-19 and Frailty. Vaccines. 2023;11:606. doi: 10.3390/vaccines11030606.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11030606</ArticleId><ArticleId IdType="pmc">PMC10057998</ArticleId><ArticleId IdType="pubmed">36992190</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Wang C., Peng M. Aging Immune System and Its Correlation With Liability to Severe Lung Complications. Front. Public Health. 2021;9:735151. doi: 10.3389/fpubh.2021.735151.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2021.735151</ArticleId><ArticleId IdType="pmc">PMC8650611</ArticleId><ArticleId IdType="pubmed">34888279</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert P.B., Montefiori D.C., McDermott A.B., Fong Y., Benkeser D., Deng W., Zhou H., Houchens C.R., Martins K., Jayashankar L., et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022;375:43–50. doi: 10.1126/science.abm3425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm3425</ArticleId><ArticleId IdType="pmc">PMC9017870</ArticleId><ArticleId IdType="pubmed">34812653</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Y., Liu X., Le W., Xie L., Li H., Wen W., Wang S., Ma S. A human circulating immune cell landscape in aging and COVID-19. Protein Cell. 2020;11:740–770. doi: 10.1007/s13238-020-00762-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13238-020-00762-2</ArticleId><ArticleId IdType="pmc">PMC7417788</ArticleId><ArticleId IdType="pubmed">32780218</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas R., Wang W., Su D. Contributions of Age-Related Thymic Involution to Immunosenescence and Inflammaging. Immun. Ageing. 2020;17:2. doi: 10.1186/s12979-020-0173-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12979-020-0173-8</ArticleId><ArticleId IdType="pmc">PMC6971920</ArticleId><ArticleId IdType="pubmed">31988649</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H. Hallmarks of the aging T-cell system. FEBS J. 2021;288:7123–7142. doi: 10.1111/febs.15770.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.15770</ArticleId><ArticleId IdType="pmc">PMC8364928</ArticleId><ArticleId IdType="pubmed">33590946</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Z., Dong X., Zhang Z., Zhang Q., Zhao Y. Aging Cell. Volume 21 John Wiley and Sons Inc.; New York, NY, USA: 2022. Age-related thymic involution: Mechanisms and functional impact.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9381902</ArticleId><ArticleId IdType="pubmed">35822239</ArticleId></ArticleIdList></Reference><Reference><Citation>Chinn I.K., Blackburn C.C., Manley N.R., Sempowski G.D. Changes in Primary Lymphoid Organs With Aging. Semin. Immunol. 2012;24:309–320. doi: 10.1016/j.smim.2012.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.smim.2012.04.005</ArticleId><ArticleId IdType="pmc">PMC3415579</ArticleId><ArticleId IdType="pubmed">22559987</ArticleId></ArticleIdList></Reference><Reference><Citation>Naylor K., Li G., Vallejo A.N., Lee W.-W., Koetz K., Bryl E., Witkowski J., Fulbright J., Weyand C.M., Goronzy J.J. The Influence of Age on T Cell Generation and TCR Diversity. J. Immunol. 2005;174:7446–7452. doi: 10.4049/jimmunol.174.11.7446.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.174.11.7446</ArticleId><ArticleId IdType="pubmed">15905594</ArticleId></ArticleIdList></Reference><Reference><Citation>Yanes R.E., Gustafson C.E., Weyand C.M., Goronzy J.J. Lymphocyte generation and population homeostasis throughout life. Semin. Hematol. 2017;54:33–38. doi: 10.1053/j.seminhematol.2016.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.seminhematol.2016.10.003</ArticleId><ArticleId IdType="pmc">PMC5260809</ArticleId><ArticleId IdType="pubmed">28088985</ArticleId></ArticleIdList></Reference><Reference><Citation>Mansourabadi A.H., Aghamajidi A., Dorfaki M., Keshavarz F., Shafeghat Z., Moazzeni A., Arab F.L., Rajabian A., Roozbehani M., Falak R., et al. B lymphocytes in COVID-19: A tale of harmony and discordance. Arch. Virol. 2023;168:148. doi: 10.1007/s00705-023-05773-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-023-05773-y</ArticleId><ArticleId IdType="pmc">PMC10147999</ArticleId><ArticleId IdType="pubmed">37119286</ArticleId></ArticleIdList></Reference><Reference><Citation>Adamo S., Chevrier S., Cervia C., Zurbuchen Y., Raeber M.E., Yang L., Sivapatham S., Jacobs A., Baechli E., Rudiger A., et al. Profound dysregulation of T cell homeostasis and function in patients with severe COVID-19. Allergy Eur. J. Allergy Clin. Immunol. 2021;76:2866–2881. doi: 10.1111/all.14866.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.14866</ArticleId><ArticleId IdType="pmc">PMC8251365</ArticleId><ArticleId IdType="pubmed">33884644</ArticleId></ArticleIdList></Reference><Reference><Citation>Richner J.M., Gmyrek G.B., Govero J., Tu Y., van der Windt G.J.W., Metcalf T.U., Haddad E.K., Textor J., Miller M.J., Diamond M.S. Age-Dependent Cell Trafficking Defects in Draining Lymph Nodes Impair Adaptive Immunity and Control of West Nile Virus Infection. PLoS Pathog. 2015;11:e1005027. doi: 10.1371/journal.ppat.1005027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1005027</ArticleId><ArticleId IdType="pmc">PMC4512688</ArticleId><ArticleId IdType="pubmed">26204259</ArticleId></ArticleIdList></Reference><Reference><Citation>Schett G., Sticherling M., Neurath M.F. COVID-19: Risk for cytokine targeting in chronic inflammatory diseases? Nat. Rev. Immunol. 2020;20:271–272. doi: 10.1038/s41577-020-0312-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0312-7</ArticleId><ArticleId IdType="pmc">PMC7186927</ArticleId><ArticleId IdType="pubmed">32296135</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolich-Žugich J. Aging of the T cell compartment in mice and humans: From no naïve expectations to foggy memories. J Immunol. 2014;193:2622–2629. doi: 10.4049/jimmunol.1401174.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1401174</ArticleId><ArticleId IdType="pmc">PMC4157314</ArticleId><ArticleId IdType="pubmed">25193936</ArticleId></ArticleIdList></Reference><Reference><Citation>Crooke S.N., Ovsyannikova I.G., Poland G.A., Kennedy R.B. Immunosenescence and human vaccine immune responses. Immun. Ageing. 2019;16:1–16. doi: 10.1186/s12979-019-0164-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12979-019-0164-9</ArticleId><ArticleId IdType="pmc">PMC6743147</ArticleId><ArticleId IdType="pubmed">31528180</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Y., Mentzer A.J., Liu G., Yao X., Yin Z., Dong D., Dejnirattisai W., Rostron T., Supasa P., Liu C., et al. Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat. Immunol. 2020;21:1336–1345. doi: 10.1038/s41590-020-0782-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-0782-6</ArticleId><ArticleId IdType="pmc">PMC7611020</ArticleId><ArticleId IdType="pubmed">32887977</ArticleId></ArticleIdList></Reference><Reference><Citation>Young A. T cells in SARS-CoV-2 infection and vaccination. Ther. Adv. Vaccines Immunother. 2022;10:25151355221115011. doi: 10.1177/25151355221115011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/25151355221115011</ArticleId><ArticleId IdType="pmc">PMC9425900</ArticleId><ArticleId IdType="pubmed">36051003</ArticleId></ArticleIdList></Reference><Reference><Citation>Rha M.S., Shin E.C. Activation or exhaustion of CD8+ T cells in patients with COVID-19. Cell. Mol. Immunol. 2021;18:2325–2333. doi: 10.1038/s41423-021-00750-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-021-00750-4</ArticleId><ArticleId IdType="pmc">PMC8374113</ArticleId><ArticleId IdType="pubmed">34413488</ArticleId></ArticleIdList></Reference><Reference><Citation>Korbi F., Zamali I., Rekik R., Ben Hmid A., Hidri M., Rebai W.K., Jelili Z., Masmoudi S., Rahal S.K., Ayed A. Ben, et al. Double-negative T cells are increased in HIV-infected patients under antiretroviral therapy. Medicine. 2022;101:E30182. doi: 10.1097/MD.0000000000030182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000030182</ArticleId><ArticleId IdType="pmc">PMC10980362</ArticleId><ArticleId IdType="pubmed">36086717</ArticleId></ArticleIdList></Reference><Reference><Citation>Petitjean G., Chevalier M.F., Tibaoui F., Didier C., Manea M.E., Liovat A.S., Campa P., Müller-Trutwin M., Girard P.M., Meyer L., et al. Level of double negative T cells, which produce TGF-β and IL-10, predicts CD8 T-cell activation in primary HIV-1 infection. AIDS. 2012;26:139–148. doi: 10.1097/QAD.0b013e32834e1484.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0b013e32834e1484</ArticleId><ArticleId IdType="pubmed">22045342</ArticleId></ArticleIdList></Reference><Reference><Citation>Cowley S.C., Meierovics A.I., Frelinger J.A., Iwakura Y., Elkins K.L. Lung CD4−CD8− Double-Negative T Cells Are Prominent Producers of IL-17A and IFN-γ during Primary Respiratory Murine Infection with Francisella tularensis Live Vaccine Strain. J. Immunol. 2010;184:5791–5801. doi: 10.4049/jimmunol.1000362.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1000362</ArticleId><ArticleId IdType="pubmed">20393138</ArticleId></ArticleIdList></Reference><Reference><Citation>Nascimbeni M., Shin E.C., Chiriboga L., Kleiner D.E., Rehermann B. Peripheral CD4+CD8+ T cells are differentiated effector memory cells with antiviral functions. Blood. 2004;104:478–486. doi: 10.1182/blood-2003-12-4395.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2003-12-4395</ArticleId><ArticleId IdType="pubmed">15044252</ArticleId></ArticleIdList></Reference><Reference><Citation>Woolthuis R.G., Van Dorp C.H., Keşmir C., De Boer R.J., Van Boven M. Long-term adaptation of the influenza A virus by escaping cytotoxic T-cell recognition. Sci. Rep. 2016;6:33334. doi: 10.1038/srep33334.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep33334</ArticleId><ArticleId IdType="pmc">PMC5024124</ArticleId><ArticleId IdType="pubmed">27629812</ArticleId></ArticleIdList></Reference><Reference><Citation>Bormann M., Brochhagen L., Alt M., Otte M., Thümmler L., van de Sand L., Kraiselburd I., Thomas A., Gosch J., Braß P., et al. Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5. Front. Immunol. 2023;14:1150667. doi: 10.3389/fimmu.2023.1150667.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1150667</ArticleId><ArticleId IdType="pmc">PMC10372796</ArticleId><ArticleId IdType="pubmed">37520539</ArticleId></ArticleIdList></Reference><Reference><Citation>Malisoux L., Backes A., Fischer A., Aguayo G., Ollert M., Fagherazzi G. Associations between physical activity prior to infection and COVID-19 disease severity and symptoms: Results from the prospective Predi-COVID cohort study. BMJ Open. 2022;12:e057863. doi: 10.1136/bmjopen-2021-057863.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2021-057863</ArticleId><ArticleId IdType="pmc">PMC9058293</ArticleId><ArticleId IdType="pubmed">35487745</ArticleId></ArticleIdList></Reference><Reference><Citation>Krzywański J., Mikulski T., Krysztofiak H., Pokrywka A., Młyńczak M., Małek Ł.A., Kwiatkowska D., Kuchar E. Elite athletes with COVID-19—Predictors of the course of disease. J. Sci. Med. Sport. 2022;25:9. doi: 10.1016/j.jsams.2021.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsams.2021.07.003</ArticleId><ArticleId IdType="pmc">PMC8277540</ArticleId><ArticleId IdType="pubmed">34334321</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell J.P., Riddell N.E., Burns V.E., Turner M., van Zanten J.J.C.S.V., Drayson M.T., Bosch J.A. Acute exercise mobilises CD8+ T lymphocytes exhibiting an effector-memory phenotype. Brain. Behav. Immun. 2009;23:767–775. doi: 10.1016/j.bbi.2009.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2009.02.011</ArticleId><ArticleId IdType="pubmed">19254756</ArticleId></ArticleIdList></Reference><Reference><Citation>Aouissi H.A., Kechebar M.S.A., Ababsa M., Roufayel R., Neji B., Petrisor A.I., Hamimes A., Epelboin L., Ohmagari N. The Importance of Behavioral and Native Factors on COVID-19 Infection and Severity: Insights from a Preliminary Cross-Sectional Study. Healthcare. 2022;10:1341. doi: 10.3390/healthcare10071341.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/healthcare10071341</ArticleId><ArticleId IdType="pmc">PMC9323463</ArticleId><ArticleId IdType="pubmed">35885867</ArticleId></ArticleIdList></Reference><Reference><Citation>Peake J.M., Neubauer O., Walsh N.P., Simpson R.J. Recovery of the immune system after exercise. J. Appl. Physiol. 2017;122:1077–1087. doi: 10.1152/japplphysiol.00622.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/japplphysiol.00622.2016</ArticleId><ArticleId IdType="pubmed">27909225</ArticleId></ArticleIdList></Reference><Reference><Citation>Supriya R., Gao Y., Gu Y., Baker J.S. Role of Exercise Intensity on Th1/Th2 Immune Modulations During the COVID-19 Pandemic. Front. Immunol. 2021;12:761382. doi: 10.3389/fimmu.2021.761382.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.761382</ArticleId><ArticleId IdType="pmc">PMC8727446</ArticleId><ArticleId IdType="pubmed">35003073</ArticleId></ArticleIdList></Reference><Reference><Citation>Filgueira T.O., Castoldi A., Santos L.E.R., de Amorim G.J., de Sousa Fernandes M.S., Anastácio W.D.L.D.N., Campos E.Z., Santos T.M., Souto F.O. The Relevance of a Physical Active Lifestyle and Physical Fitness on Immune Defense: Mitigating Disease Burden, With Focus on COVID-19 Consequences. Front. Immunol. 2021;12:587146. doi: 10.3389/fimmu.2021.587146.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.587146</ArticleId><ArticleId IdType="pmc">PMC7892446</ArticleId><ArticleId IdType="pubmed">33613573</ArticleId></ArticleIdList></Reference><Reference><Citation>Young D.R., Sallis J.F., Baecker A., Cohen D.A., Nau C.L., Smith G.N., Sallis R.E. Associations of Physical Inactivity and COVID-19 Outcomes Among Subgroups. Am. J. Prev. Med. 2023;64:492–502. doi: 10.1016/j.amepre.2022.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amepre.2022.10.007</ArticleId><ArticleId IdType="pmc">PMC9750896</ArticleId><ArticleId IdType="pubmed">36528452</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen D.Y., Chin C.V., Kenney D., Tavares A.H., Khan N., Conway H.L., Liu G.Q., Choudhary M.C., Gertje H.P., O’Connell A.K., et al. Spike and nsp6 are key determinants of SARS-CoV-2 Omicron BA.1 attenuation. Nature. 2023;615:143–150. doi: 10.1038/s41586-023-05697-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-05697-2</ArticleId><ArticleId IdType="pubmed">36630998</ArticleId></ArticleIdList></Reference><Reference><Citation>Diep A.N., Schyns J., Gourzones C., Goffin E., Papadopoulos I., Moges S., Minner F., Ek O., Bonhomme G., Paridans M., et al. How do successive vaccinations and SARS-CoV-2 infections impact humoral immunity dynamics: An 18-month longitudinal study. J. Infect. 2024;88:183–186. doi: 10.1016/j.jinf.2023.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2023.11.006</ArticleId><ArticleId IdType="pubmed">37981216</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagiu B.A. Moderate exercise may prevent the development of severe forms of COVID-19, whereas high-intensity exercise may result in the opposite. Med. Hypotheses. 2021;157:110705. doi: 10.1016/j.mehy.2021.110705.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2021.110705</ArticleId><ArticleId IdType="pmc">PMC8520569</ArticleId><ArticleId IdType="pubmed">34670172</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>